This study investigates the influence of fibroblast growth factor receptor type B (FGFRb) and fibroblast growth factor on cervical carcinogenesis associated with HPV16 E6/7 infection, using primary cancer cells isolated from Taiwanese patients with cervical cancer. Functional interaction between FGFRb in Cx cells and HPV16 E6/7 transfected Cx cells (CxWJ cells) following treatment with FGF-7, according to cell growth, invasive ability, and tumor growth in SCID mice. Our results indicate that the downregulation of FGFRb gene expression in CxWJ cells partially represses proliferation and the invasive ability provided by FGF-7 stimulation. In SCID mice, the FGF2 and FGFR1 gene expression ascend in CxWJ tumor nodule. These data provide evidence of a functional interaction between HPV16 E6/7 in FGFRb and FGF2, suggesting that cooperative stimulation of HPV E6/7 in inactivated FGFRb and the upregulation of FGF2 may be necessary to completely overcome the oncogenic function associated with the progression of cervical carcinogenesis.
HsuKFWuCLHuangSC. Conditionally replicating E1B-deleted adenovirus driven by the squamous cell carcinoma antigen 2 promoters for uterine cervical cancer therapy. Cancer Gene Ther. 2008;15(8):526–534.
2.
LangHCWuSL.Lifetime costs of the top five cancers in Taiwan. Eur J Health Econ. 2011 Mar 27. DOI: 10.1007/s10198-011-0307-1.
3.
ChenCCLinJCJanJS. Definitive intensity-modulated radiation therapy with concurrent chemotherapy for patients with locally advanced cervical cancer. Gynecol Oncol. 2011;122(1):9–13.
4.
SubaEJMichelowPMRaabSS. Human papillomavirus testing in the prevention of cervical cancer. J Natl Cancer Inst. 2011;103(19):368–383.
5.
MühlenSBehrenAIftnerTSimonC. Influence of HPV16 E2 and its localisation on the expression of matrix metalloproteinase-9. Int J Oncol. 2010;37(2):337–345.
6.
NoJHKimMKJeonYTKimYBSongYS. Human papillomavirus vaccine: widening the scope for cancer prevention. Mol Carcinog. 2011;50(4):244–253.
7.
ZollnerUSchwarzTF. Diseases caused by human papilloma viruses. Dtsch Med Wochenschr. 2011;136(20):1067–1072.
8.
ChenGJForoughR. Fibroblast growth factors, fibroblast growth factor receptors, diseases, and drugs. Recent Pat Cardiovasc Drug Discov. 2006;1(2):211–224.
9.
UcuzianAABrewsterLPEastATPangYGassmanAAGreislerHP. Characterization of the chemotactic and mitogenic response of SMCs to PDGF-BB and FGF-2 in fibrin hydrogels. J Biomed Mater Res A. 2010;94(3):988–996.
10.
CaverzasioJThouvereyC. Activation of FGF receptors is a new mechanism by which strontium ranelate induces osteoblastic cell growth. Cell Physiol Biochem. 2011;27(3-4):243–250.
11.
SchwertfegerKL. Fibroblast growth factors in development and cancer: insights from the mammary and prostate glands. Curr Drug Targets. 2009;10(7):632–644.
12.
ManuvakhovaMThottasseryJVHaysS. Expression of the SNT-1/FRS2 phosphotyrosine binding domain inhibits activation of MAP kinase and PI3-kinase pathways and antiestrogen resistant growth induced by FGF-1 in human breast carcinoma cells. Oncogene. 2006;25(44):6003–6014.
13.
SteeleIAEdmondsonRJBulmerJNBolgerBSLeungHYDaviesBR. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene. 2001;20(41):5878–5887.
14.
ChaJYLambertQTReutherGWDerCJ. Involvement of fibroblast growth factor receptor 2 isoform switching in mammary oncogenesis. Mol Cancer Res. 2008;6(3):435–445.
15.
OlteanSSorgBSAlbrechtT. Alternative inclusion of fibroblast growth factor receptor 2 exon IIIc in Dunning prostate tumors reveals unexpected epithelial mesenchymal plasticity. Proc Natl Acad Sci U S A. 2006;103(38):14116–14121.
16.
TsaiSMWangWP. Expression and function of fibroblast growth factor (FGF) 7 during liver regeneration. Cell Physiol Biochem. 2011;27(6):641–652.
17.
De AndradeJAThannickalVJ. Innovative approaches to the therapy of fibrosis. Curr Opin Rheumatol. 2009;21(6):649–655.
18.
YanaiMTatsumiNHasunumaNKatsuKEndoFYokouchiY. FGF signaling segregates biliary cell-lineage from chick hepatoblasts cooperatively with BMP4 and ECM components in vitro. Dev Dyn. 2008;237(5):1268–1283.
19.
BöhmFSpeicherTHellerbrandC. FGF receptors 1 and 2 control chemically induced injury and compound detoxification in regenerating livers of mice. Gastroenterology. 2010;139(4):1385–1396.
20.
HalbertCLDemersGWGallowayDA. The E7 gene of human papillomavirus type 16 is sufficient for immortalization of human epithelial cells. J Virol. 1991;65(1):473–478.
21.
ChouCYChenYHTzengCCChengYCChangCFChenTM. Establishment and characterization of a human-papillomavirus negative, p53-mutation negative human cervical cancer cell line. Cancer Lett. 1996;102(1-2):173–181.
22.
KimJKimPHYooJY. Double E1B 19 kDa- and E1B 55 kDa-deleted oncolytic adenovirus in combination with radiotherapy elicits an enhanced anti-tumor effect. Gene Ther. 2009;16(9):1111–1121.
23.
ChenMJTangWYHsuCW. Apoptosis induction in primary human colorectal cancer cell lines and retarded tumor growth in SCID mice by sulforaphane. Evid Based Complement Alternat Med. 2012;2012:415231.
24.
Abu-RustumNRSonodaY. Fertility-sparing surgery in early-stage cervical cancer: indications and applications. J Natl Compr Canc Netw. 2010;8(12):1435–1438.
25.
MunagalaRKausarHMunjalCGuptaRC. Withaferin A induces p53-dependent apoptosis by repression of HPV oncogenes and up-regulation of tumor suppressor proteins in human cervical cancer cells. Carcinogenesis. 2011:32(11):1697–1705.
26.
CiottiMSestiFPabaP. Human papillomavirus (HPV) testing in the management of women with abnormal pap smears. Experience of a colposcopy referral clinic. Eur J Gynaecol Oncol. 2004;25(5):577–584.
27.
SteeleIAEdmondsonRJBulmerJNBolgerBSLeungHYDaviesBR. Induction of FGF receptor 2-IIIb expression and response to its ligands in epithelial ovarian cancer. Oncogene. 2001;20(41):5878–5887.
28.
DuchesneLTissotBRuddTRDellAFernigDG. N-glycosylation of fibroblast growth factor receptor 1 regulates ligand and heparan sulfate co-receptor binding. J Biol Chem. 2006;281(37):27178–27189.
29.
SteeleIAEdmondsonRJLeungHYDaviesBR. Ligands to FGF receptor 2-IIIb induce proliferation, motility, protection from cell death and cytoskeletal rearrangements in epithelial ovarian cancer cell lines. Growth Factors. 2006;24(1):45–53.
30.
LiTJiangS. Effect of bFGF on invasion of ovarian cancer cells through the regulation of Ets-1 and urokinase-type plasminogen activator. Pharm Biol. 2010;48(2):161–165.
31.
KottakisFPolytarchouCFoltopoulouPSanidasIKampranisSCTsichlisPN. FGF-2 Regulates Cell Proliferation, Migration, and Angiogenesis through an NDY1/KDM2B-miR-101-EZH2 Pathway. Mol Cell. 2011;43(2):285–298.
32.
JohanssonARudolfssonSHammarstenP. Mast cells are novel independent prognostic markers in prostate cancer and represent a target for therapy. Am J Pathol. 2010;177(2):1031–1041.
